Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy Vollmer

Showing results (71-80 of 77) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 77 results.
Therapeutic Advances in Neurological Disorders|October 14, 2024
Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trialsTobias Derfuss, Robert Bermel, Chien-Ju Lin, et al.
The Lancet. Neurology|April 2, 2014
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trialPeter A Calabresi, Ernst-Wilhelm Radue, Douglas Goodin, et al.
Journal of Neurology|April 22, 2024
ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trialHans-Peter Hartung, Thomas Berger, Robert A Bermel, et al.
Neurology|January 30, 2025
Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label ExtensionJoão J Cerqueira, Achim Berthele, Bruce A C Cree, et al.
Archives of Neurology|August 19, 2007
Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trialAmit Bar-Or, Timothy Vollmer, Jack Antel, et al.
Neurology|December 3, 2024
Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label TrialHans-Peter Hartung, Ralph H B Benedict, Thomas Berger, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 2, 2018
International consensus on quality standards for brain health-focused care in multiple sclerosisJeremy Hobart, Amy Bowen, George Pepper, et al.
Pageof 8

Showing results (71-80 of 77) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 77 results.
Therapeutic Advances in Neurological Disorders|October 14, 2024
Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trialsTobias Derfuss, Robert Bermel, Chien-Ju Lin, et al.
The Lancet. Neurology|April 2, 2014
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trialPeter A Calabresi, Ernst-Wilhelm Radue, Douglas Goodin, et al.
Journal of Neurology|April 22, 2024
ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trialHans-Peter Hartung, Thomas Berger, Robert A Bermel, et al.
Neurology|January 30, 2025
Long-Term Treatment With Ocrelizumab in Patients With Early-Stage Relapsing MS: Nine-Year Data From the OPERA Studies Open-Label ExtensionJoão J Cerqueira, Achim Berthele, Bruce A C Cree, et al.
Archives of Neurology|August 19, 2007
Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trialAmit Bar-Or, Timothy Vollmer, Jack Antel, et al.
Neurology|December 3, 2024
Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis: The Phase IIIb ENSEMBLE 4-Year, Single-Arm, Open-Label TrialHans-Peter Hartung, Ralph H B Benedict, Thomas Berger, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 2, 2018
International consensus on quality standards for brain health-focused care in multiple sclerosisJeremy Hobart, Amy Bowen, George Pepper, et al.
Pageof 8